FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “ RenovoRx, Inc. Receives New 510(k) Clearance For RenovoCath Delivery System”
RenovoRx, Inc. (NASDAQ: RNXT) surged over 40% in premarket trading after the company announced that it had received a new 510(k) clearance from the U.S. FDA for its proprietary RenovoCath Delivery System.
The RenovoCath Delivery System is the device component of the Company’s initial product, RenovoGem and the new design provides more targeted delivery of therapy which the Company believes can translate into more effective treatment with fewer side effects.
RenovoRx, a biopharmaceutical company headquartered in Silicon Valley, California, has developed a therapy platform targeting difficult-to-treat tumors. Targeted therapy via the proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMP) platform safely and without transmission to non-targeted areas, is the primary focus.
For more information, please visit: RenovoRx, Inc.
About The Buzz: A Financial Buzz Show on daily news, covering the most up to date financial information. The Buzz intends to provide factual and relevant information for its audience. The Buzz is 100% original content, created by Financial Buzz Media. Located on Wall Street in the heart of New York City’s financial district, FinancialBuzz.com is a credible source for the world’s latest trending financial and economic news. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content.
The post “The Buzz” Show: RenovoRx, Inc. (NASDAQ: RNXT) 510(k) Clearance For RenovoCath Delivery System first appeared on Financial Buzz .
For further details see:
“The Buzz” Show: RenovoRx, Inc. (NASDAQ: RNXT) 510(k) Clearance For RenovoCath Delivery System